Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

Executive Summary

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

You may also be interested in...



Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22

Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22

Invega Review Shows FDAers At Odds On Safety Issues

FDA review documents illustrate internal disagreement at the division level during the agency's review of Johnson & Johnson's schizophrenia agent Invega. The review also highlights the difficulty in assessing safety in the unique patient population affected by schizophrenia

Related Content

UsernamePublicRestriction

Register

PS047871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel